---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-030952"
form_type: "8-K"
ticker: "NSYS"
cik: "0000722313"
company_name: "NORTECH SYSTEMS INC"
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T11:59:46.172021+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nortech Systems Q3 revenue down 5.4% to $33.4M; EPS $0.42 vs $0.53 prior; backlog $102M

## Summary
- Revenue $33.4M, down 5.4% YoY; GAAP net income $1.2M ($0.42 diluted EPS) vs $1.5M ($0.53) in Q3 2022.
- Gross margin 15.9%, up 30 bps from Q2 2023; EBITDA $1.6M flat with Q2 2023.
- Backlog $102M at Sept 30, up slightly; YTD revenue $103.3M, up 4.8% from prior year.
- Management cites two large customers pushing out orders; expects resolution near term.
- Suzhou China facility earned Class II Medical Device certification from China NMPA, boosting medical sales in Asia.

## SEC filing metadata
- accession: 0001437749-23-030952
- form_type: 8-K
- ticker: NSYS
- cik: 0000722313
- company_name: NORTECH SYSTEMS INC
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/722313/000143774923030952/0001437749-23-030952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/722313/000143774923030952/nsys20231108_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-030952
- JSON: https://secwatch.observer/filing/0001437749-23-030952.json
- Plain text: https://secwatch.observer/filing/0001437749-23-030952.txt

## Key facts
- Earnings Releases
  NORTECH SYSTEMS INC reported third quarter ended September 30, 2023 results: revenue $33,369, net income $1,207, EPS $0.42 per diluted share.
  - Period: third quarter ended September 30, 2023
  - Revenue: $33,369
  - Net income: $1,207
  - EPS: $0.42 per diluted share
  - Result: reported results
  source text: across our medical, industrial and defense markets.” 2023 Third Quarter Results In $000, except EBITDA Q3 23 Q3 22 % Favorable YTD 2023 YTD 2022 % Favorable Revenue $33,369 $35,276 (5.4) % $103,278 $98,505 4.8% Gross Profit $5,319 $6,328 (16.0) % $16,277 $15,376 5.9% Operating Expenses $4,195 $4,383 4.3% $13,000 $12,237 (6.2) % Net Income $1,207
  evidence_url: https://www.sec.gov/Archives/edgar/data/722313/000143774923030952/0001437749-23-030952-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.